{"id":2183,"name":"Ally Bridge Group","slug":"ally-bridge-group","website":"https://www.centerbridge.com/","hqGeo":"Hong Kong, China","stageFocus":["Pre-Seed","Seed","Series A"],"sectorTags":["Healthcare","Other"],"excludedSectors":[],"checkSizeMin":200000,"checkSizeMax":5000000,"thesisSummary":"Ally Bridge Group is dedicated to innovative life science investments, including pharmaceutical technologies and cloud-enabled health solutions.","thesisNarrative":null,"logoUrl":null,"aumUsd":3000000000,"submissionUrl":null,"linkedinUrl":null,"twitterHandle":null,"portfolio":[{"companyName":"OrigiMed","companyUrl":null,"stage":null,"sector":"Pharma Tech","investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"ThermoGenesis","companyUrl":null,"stage":null,"sector":"Biotech","investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Aerin Medical","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Arbor Biotechnologies","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"BenevolentAI","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Biobeat","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Cardiac Dimensions","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Ceribell","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"CMR Surgical","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Elligo Health Research","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Endeavor BioMedicines","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Epicrispr Biotechnologies","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Imperative Care","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Insightec","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Kestra Medical Technologies","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"LightForce","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Luoxin Pharmaceuticals Group","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Mainstay Medical","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Mavrik Dental Systems","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"MedAvail","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Mission Bio","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"ProfoundBio","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Pulmonx","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Quantum Surgical","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Rapid Micro Biosystems","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"RefleXion Medical","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null}],"partnerCount":20,"partners":[{"id":6065,"name":"Kevin Reilly","title":"Managing Director","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/kevin-reilly-0b786812","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":6066,"name":"Keith Lee","title":"Vice President","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/keithlee0204","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":12831,"name":"Sam Brodovsky","title":"Associate","seniority":null,"focusTags":["investments in medical technology"],"linkedinUrl":"https://www.linkedin.com/in/sam-brodovsky-12528990","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":"Sam Brodovsky joined Ally Bridge Group in 2024 and is a Senior Associate for the private equity strategy focused on investments in medical technology. Prior to joining Ally Bridge Group, Sam was a Medical Device Equity Research Analyst at Truist Securities.","recentPosts":[]},{"id":6064,"name":"Charles Wong","title":"Chief Financial Officer","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/charles903","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":2216,"name":"Frank Yu","title":"Founder & CEO","seniority":null,"focusTags":["Pharma Tech","HealthTech"],"linkedinUrl":"https://www.linkedin.com/in/frank-yu-allybridge","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":12835,"name":"Tony Deng","title":"Associate","seniority":null,"focusTags":["investments in therapeutics"],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":"Tony Deng joined Ally Bridge Group in 2025 and is an Analyst for the public equity strategy focused on investments in therapeutics. Before joining Ally Bridge Group, Tony worked as a Vice President at Barclays in SMID-cap biotech equity research.","recentPosts":[]},{"id":12836,"name":"Ting Liu","title":"Associate","seniority":null,"focusTags":["therapeutics investments"],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":"Ting Liu is an Analyst at Ally Bridge Group’s public equity strategy, focusing on therapeutics investments. She previously served as Director/Analyst at UBS and Senior Associate at RBC Capital Markets in Biotech Equity Research.","recentPosts":[]},{"id":12830,"name":"Stephen Mallon","title":"Vice President Private Equity","seniority":null,"focusTags":["investments in therapeutics"],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":"Stephen Mallon, PhD joined Ally Bridge Group in 2022 and is a Vice President for the private equity strategy focused on investments in therapeutics. Before joining Ally Bridge Group, Stephen was a Senior Research Associate at Royal Bank of Canada Capital Markets. Prior to that, Stephen was a Senior Research Associate at Chardan Capital Markets.","recentPosts":[]},{"id":12833,"name":"Slanix Paul Alex","title":"Portfolio Manager and President Public Equity","seniority":null,"focusTags":["public equity strategy"],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":"Slanix Paul Alex joined Ally Bridge Group in 2023 and is the Portfolio Manager and President for the public equity strategy. Before joining Ally Bridge Group, Slanix invested in life sciences companies as founding Partner and Senior Analyst for Tri Locum Partners.","recentPosts":[]},{"id":12826,"name":"Andrew Lam","title":"Managing Partner","seniority":null,"focusTags":["investments in biotech"],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":"Andrew Lam joined Ally Bridge Group in 2021 and is a Managing Director, Head of Biotech, for the private equity strategy focused on investments in biotech. Before joining Ally Bridge Group, Andrew was Senior Director of Business Development at Intercept Pharmaceuticals. Before that, Andrew was a Vice President, Healthcare Investment Banking at Jefferies and an Equity Research Associate at BMO Capital and Canaccord Genuity. Andrew began his career at several biotechnology companies, including Celgene and Shire.","recentPosts":[]},{"id":12829,"name":"Megan MacDonagh","title":"Vice President Private Equity","seniority":null,"focusTags":["investments in medical devices and digital health"],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":"Megan MacDonagh joined Ally Bridge Group in 2025 and is a Vice President for the private equity strategy focused on investments in medical devices and digital health. Before joining Ally Bridge Group, Megan was a Vice President at SV Health Investors, where she focused on early-stage and growth-stage medical device and digital health investments.","recentPosts":[]},{"id":6067,"name":"Zain Shekhani","title":"Managing Director","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/zain-shekhani-75529523","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":12827,"name":"Carlos Solorzano","title":"Principal","seniority":null,"focusTags":["investments in biotech"],"linkedinUrl":"https://www.linkedin.com/in/cesolorzano","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":"Carlos joined Ally Bridge Group in 2024 and is a Principal for the private equity strategy focused on investments in biotech. Before joining Ally Bridge, Carlos was in the investment teams at Section 32 and Pivotal bioVenture Partners focused on private biotech companies. Before his career in private equity, Carlos was in the BD and Corporate Strategy team at Ultragenyx and was a Senior Associate in the equity research teams at Deutsche Bank and Oppenheimer & Co.","recentPosts":[]},{"id":6068,"name":"Michael Bendetson","title":"Chief Operating Officer","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/michael-bendetson-076061176","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":6069,"name":"Steven Plachtyna","title":"Vice President","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/steven-plachtyna","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":6070,"name":"Reese Yeh","title":"Managing Director","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/reese-yeh-31a30027","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":12828,"name":"Jonathan Wang","title":"Vice President Private Equity","seniority":null,"focusTags":["private equity strategy"],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":"Jonathan Wang joined Ally Bridge Group in 2021 and is a Vice President for the private equity strategy. Before joining Ally Bridge Group, Jonathan worked as an Investment Manager at Navis Capital Partners. Before that, Jonathan worked in PricewaterhouseCoopers’ Transaction Services division.","recentPosts":[]},{"id":6063,"name":"Paresh Kumar","title":"Vice President of Biotechnology Private Equity","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/kumarparesh","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":12834,"name":"Evan Zou","title":"Associate","seniority":null,"focusTags":["investments in therapeutics"],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":"Evan Zou joined Ally Bridge Group in 2022 and is a Senior Analyst for the public equity strategy focused on investments in therapeutics. Before joining Ally Bridge Group, Evan was an Associate Director on the Portfolio Intelligence team at BridgeBio Pharma.","recentPosts":[]},{"id":12832,"name":"Srishti Kotiyal","title":"Associate","seniority":null,"focusTags":["investments in biotech"],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":"Srishti Kotiyal joined Ally Bridge Group in 2024 and is an Associate for the private equity strategy focused on investments in biotech. Before joining Ally Bridge Group, Srishti was an Associate in the Healthcare Investment Banking Group at Jefferies.","recentPosts":[]}],"funds":[],"activity":{"lastInvestmentYear":null,"investmentsLast12Months":0},"investorType":"vc","preferredApproach":"warm intro preferred","prefersFounderType":null,"oneClickPitchEnabled":false,"relatedFirms":[{"id":12955,"name":"Jovono","slug":"jovono","logoUrl":null,"website":"https://jovono.com","stageFocus":["Seed","Series A"],"sectorTags":["Other","Climate / Energy","Fintech","Consumer","SaaS","Healthcare"],"hqGeo":"Los Angeles, CA"},{"id":13015,"name":"Nile Ventures","slug":"nile-ventures-13015","logoUrl":null,"website":"https://www.choosenile.com/","stageFocus":["Pre-Seed"],"sectorTags":["Healthcare","SaaS"],"hqGeo":"Lagos, Nigeria"},{"id":9065,"name":"Sdv","slug":"sdv","logoUrl":null,"website":"https://sdv.vc","stageFocus":["Pre-Seed","Seed"],"sectorTags":["SaaS","Fintech","Healthcare","AI / ML"],"hqGeo":null},{"id":13026,"name":"Robin Capital","slug":"robin-capital","logoUrl":null,"website":"https://robincap.com/","stageFocus":["Pre-Seed","Seed"],"sectorTags":["AI / ML","Fintech","SaaS","Other","Climate / Energy","Healthcare"],"hqGeo":"Berlin, Germany"},{"id":10202,"name":"Celestial Health Innovators","slug":"celestial-health-innovators","logoUrl":null,"website":"https://celestialhealthwellness.co/","stageFocus":["seed+","Series A"],"sectorTags":["Healthcare","Other"],"hqGeo":"New York, NY"},{"id":12096,"name":"TeleHealth Ventures","slug":"telehealth-ventures","logoUrl":null,"website":"https://telehealthventures.com","stageFocus":["Seed"],"sectorTags":["Other","Healthcare"],"hqGeo":"Austin, TX"}],"featuredIn":[{"slug":"pre-seed","displayName":"Pre-Seed Investors","pageType":"stage"},{"slug":"seed","displayName":"Seed Investors","pageType":"stage"},{"slug":"healthcare","displayName":"Healthcare Investors","pageType":"industry"}],"fundraisingResources":[{"slug":"what-vcs-actually-look-for-pitch-deck","title":"What VCs Actually Look for in a Pitch Deck"},{"slug":"find-right-pre-seed-investors-b2b-saas","title":"How to Find the Right Pre-Seed Investors for Your B2B SaaS Startup"},{"slug":"Finding-Investors-For-Startup-In-2026","title":"How to Find Investors for Your Startup in 2026 (Without Cold-Searching Databases)"}],"overviewNarrative":null,"portfolioNarrative":null,"seoTitle":"Ally Bridge Group: Check Size, Portfolio & How to Pitch (2026)","seoDescription":"Ally Bridge Group invests $200K–$5M in life sciences and health tech from Hong Kong. $3B AUM, 27 portfolio companies. See thesis, partners, and how to pitch.","lastVerifiedAt":"2026-05-04T01:46:23.145Z"}